FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2044387730> ?p ?o ?g. }

• W2044387730 endingPage "A431" @default.
• W2044387730 startingPage "A431" @default.
• W2044387730 abstract "Ultra-orphan diseases affect a very small patient population, defined by the National Institute for Health and Care Excellence (NICE) as those diseases with a prevalence of ≤ 1: 50,000. Medicines for these indications are difficult to develop in part due to challenges associated with recruiting for clinical trials from a small patient population. Within this context, global payer bodies have assessed these therapies with modified evidence requirements and opportunity for very high prices. We performed a health technology assessment (HTA) review of two ultra-orphan products – eculizumab/Soliris and iduronate-2-sulfatase (IDS) /Elaprase – to gain insight into the evolving HTA evidence requirements for ultra-orphan medicines and comparatively evaluate key decision drivers across geographies. We scanned global HTAs published before end of May 2014 to identify the two most widely assessed ultra-orphan therapies that have variable reimbursement decision outcomes (eculizumab/Soliris and IDS/Elaprase). To evaluate pivotal decision drivers, we analyzed HTAs across several criteria, including clinical efficacy, unmet need, strength of evidence, cost-effectiveness and burden of illness. We identified HTAs in seven countries. For both products, reimbursement decisions varied across agencies. Key decision drivers included cost-effectiveness, clinical efficacy, risk-sharing schemes, and lowered evidence requirements/ special criteria for ultra-orphan medicines. Assessments rejecting Soliris and Elaprase (e. g., Australia, Canada, UK) did so based on cost-effectiveness and lack of long-term survival data. Notably, the NICE Highly Specialized Technology Committee requested unprecedented justification of Soliris pricing. Some agencies (e. g, Scottish Medicines Consortium [SMC] ) preemptively rejected the products due to manufacturer non-submission of required data. In Australia, Soliris gained recommendation alongside a risk-sharing scheme while Elaprase gained recommendation under Life Saving Drugs Program criteria. Eculizumab and IDS are among a select list of therapies commanding very high prices globally. This study demonstrates variability in decision criteria and approaches across HTA agencies for such high-priced ultra-orphan products." @default.
• W2044387730 created "2016-06-24" @default.
• W2044387730 creator A5001573379 @default.
• W2044387730 creator A5001824262 @default.
• W2044387730 creator A5031248794 @default.
• W2044387730 creator A5069403648 @default.
• W2044387730 creator A5072984827 @default.
• W2044387730 creator A5033423988 @default.
• W2044387730 date "2014-11-01" @default.
• W2044387730 modified "2023-09-25" @default.
• W2044387730 title "Global HTA Assessments of Ultra-Orphan Products: A Case Study Of Eculizumab (Soliris) and Iduronate-2-Sulfatase (Elaprase)" @default.
• W2044387730 doi "https://doi.org/10.1016/j.jval.2014.08.1098" @default.
• W2044387730 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27201127" @default.
• W2044387730 hasPublicationYear "2014" @default.
• W2044387730 type Work @default.
• W2044387730 sameAs 2044387730 @default.
• W2044387730 citedByCount "0" @default.
• W2044387730 crossrefType "journal-article" @default.
• W2044387730 hasAuthorship W2044387730A5001573379 @default.
• W2044387730 hasAuthorship W2044387730A5001824262 @default.
• W2044387730 hasAuthorship W2044387730A5031248794 @default.
• W2044387730 hasAuthorship W2044387730A5033423988 @default.
• W2044387730 hasAuthorship W2044387730A5069403648 @default.
• W2044387730 hasAuthorship W2044387730A5072984827 @default.
• W2044387730 hasBestOaLocation W20443877301 @default.
• W2044387730 hasConcept C111684460 @default.
• W2044387730 hasConcept C112930515 @default.
• W2044387730 hasConcept C144133560 @default.
• W2044387730 hasConcept C159654299 @default.
• W2044387730 hasConcept C160735492 @default.
• W2044387730 hasConcept C162324750 @default.
• W2044387730 hasConcept C166957645 @default.
• W2044387730 hasConcept C17744445 @default.
• W2044387730 hasConcept C199360897 @default.
• W2044387730 hasConcept C199539241 @default.
• W2044387730 hasConcept C203014093 @default.
• W2044387730 hasConcept C205649164 @default.
• W2044387730 hasConcept C21333345 @default.
• W2044387730 hasConcept C2777352838 @default.
• W2044387730 hasConcept C2777991916 @default.
• W2044387730 hasConcept C2779256446 @default.
• W2044387730 hasConcept C2779343474 @default.
• W2044387730 hasConcept C2779703844 @default.
• W2044387730 hasConcept C2908647359 @default.
• W2044387730 hasConcept C3019080777 @default.
• W2044387730 hasConcept C41008148 @default.
• W2044387730 hasConcept C50522688 @default.
• W2044387730 hasConcept C512399662 @default.
• W2044387730 hasConcept C60644358 @default.
• W2044387730 hasConcept C71924100 @default.
• W2044387730 hasConcept C75480439 @default.
• W2044387730 hasConcept C86803240 @default.
• W2044387730 hasConcept C99454951 @default.
• W2044387730 hasConceptScore W2044387730C111684460 @default.
• W2044387730 hasConceptScore W2044387730C112930515 @default.
• W2044387730 hasConceptScore W2044387730C144133560 @default.
• W2044387730 hasConceptScore W2044387730C159654299 @default.
• W2044387730 hasConceptScore W2044387730C160735492 @default.
• W2044387730 hasConceptScore W2044387730C162324750 @default.
• W2044387730 hasConceptScore W2044387730C166957645 @default.
• W2044387730 hasConceptScore W2044387730C17744445 @default.
• W2044387730 hasConceptScore W2044387730C199360897 @default.
• W2044387730 hasConceptScore W2044387730C199539241 @default.
• W2044387730 hasConceptScore W2044387730C203014093 @default.
• W2044387730 hasConceptScore W2044387730C205649164 @default.
• W2044387730 hasConceptScore W2044387730C21333345 @default.
• W2044387730 hasConceptScore W2044387730C2777352838 @default.
• W2044387730 hasConceptScore W2044387730C2777991916 @default.
• W2044387730 hasConceptScore W2044387730C2779256446 @default.
• W2044387730 hasConceptScore W2044387730C2779343474 @default.
• W2044387730 hasConceptScore W2044387730C2779703844 @default.
• W2044387730 hasConceptScore W2044387730C2908647359 @default.
• W2044387730 hasConceptScore W2044387730C3019080777 @default.
• W2044387730 hasConceptScore W2044387730C41008148 @default.
• W2044387730 hasConceptScore W2044387730C50522688 @default.
• W2044387730 hasConceptScore W2044387730C512399662 @default.
• W2044387730 hasConceptScore W2044387730C60644358 @default.
• W2044387730 hasConceptScore W2044387730C71924100 @default.
• W2044387730 hasConceptScore W2044387730C75480439 @default.
• W2044387730 hasConceptScore W2044387730C86803240 @default.
• W2044387730 hasConceptScore W2044387730C99454951 @default.
• W2044387730 hasIssue "7" @default.
• W2044387730 hasLocation W20443877301 @default.
• W2044387730 hasLocation W20443877302 @default.
• W2044387730 hasOpenAccess W2044387730 @default.
• W2044387730 hasPrimaryLocation W20443877301 @default.
• W2044387730 hasRelatedWork W2155508065 @default.
• W2044387730 hasRelatedWork W2224694783 @default.
• W2044387730 hasRelatedWork W2626412868 @default.
• W2044387730 hasRelatedWork W2766231777 @default.
• W2044387730 hasRelatedWork W2811334505 @default.
• W2044387730 hasRelatedWork W2995092704 @default.
• W2044387730 hasRelatedWork W2997067502 @default.
• W2044387730 hasRelatedWork W4205121259 @default.
• W2044387730 hasRelatedWork W4307746163 @default.
• W2044387730 hasRelatedWork W4311339323 @default.
• W2044387730 hasVolume "17" @default.
• W2044387730 isParatext "false" @default.

• next